PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism | Bentham Science
Peroxisome proliferator‐activated receptor‐γ: too much of a good thing causes harm | EMBO reports
Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway - ScienceDirect
Measuring biomarkers to assess the therapeutic effects of PPAR agonists? | Pharmacogenomics
Re-highlighting the action of PPARγ in... | F1000Research
The therapeutic potential of inhibiting PPARγ phosphorylation to treat type 2 diabetes - ScienceDirect
Peroxisome proliferator-activated receptor γ in diabetes and metabolism - ScienceDirect
The Many Faces of PPARγ: Cell
Saroglitazar for the treatment of hypertriglyceridemia in patients wit | DMSO
Mechanism by which of PPAR γ ligands regulate insulin sensitivity. In... | Download Scientific Diagram
Gescheiterte PPAR-Agonisten: Glitazare und GLP-1 – neuer Ansatz bei Diabetes ?
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? | International Journal of Obesity
Therapeutic potential of PPARγ natural agonists in liver diseases - Wu - 2020 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Diabetes & Metabolism Journal
Peroxisom-Proliferator-aktivierte Rezeptoren – Wikipedia
Frontiers | The Protective Effects of Peroxisome Proliferator-Activated Receptor Gamma in Cerebral Ischemia-Reperfusion Injury
PDF] A clinical update on peroxisome proliferator-activated receptors | Semantic Scholar
Molecules | Free Full-Text | Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease
Endocrinologic and Metabolic Drugs Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Preclinical and Clinical Cardiac Safety Considerations Jeri. - ppt download
Frontiers | The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators